Stockreport

Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update

Cardiff Oncology, Inc.  (CRDF) 
PDF - Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bev in second-line KRAS mutant mCRC in the peer-reviewed Journal of Clinical On [Read more]